Results 211 to 220 of about 656,651 (288)

A Next‐Generation ELISA for the Detection of Anti‐(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID‐19 Vaccinated Individuals

open access: yesJournal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.
ABSTRACT Background and Aims Autoimmune nodopathy (AN) is a subtype of antibody‐mediated inflammatory neuropathy targeting the node of Ranvier (NoR). Diagnosis requires detection of anti‐(para)nodal autoantibodies like contactin‐1 and neurofascin‐155 via ELISA or cell‐based assays, but protocols are inconsistent. Causes of node autoimmunity are unknown,
Luise Appeltshauser   +9 more
wiley   +1 more source

Towards Geographies of Silence: Unspoken Boundaries

open access: yesTransactions of the Institute of British Geographers, Volume 51, Issue 2, June 2026.
ABSTRACT Despite its social and spatial significance, silence remains an under‐explored and under‐theorised subject in geography. This paper addresses this lacuna by examining silence as a boundary‐making practice in geographically distant relationships.
Dora Sampaio
wiley   +1 more source

Clinical, morphological, and molecular characterization of patients with X-linked myopathy with excessive autophagy (XMEA). [PDF]

open access: yesJ Neuropathol Exp Neurol
Merlet AN   +20 more
europepmc   +1 more source

Digital Connections, Social Cohesion and Trust—Comparative Evidence From Rural and Urban Communities in Germany

open access: yesJournal of Community &Applied Social Psychology, Volume 36, Issue 3, May/June 2026.
ABSTRACT This study investigates the role of digital information and communication technologies (DICT) in the context of social cohesion and trust (SCT) at the community level. The analysis is grounded in the assumption that SCT underpins both social capital and the capacity for collective action in communities.
Yann P. M. Rees   +3 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy